timothy sykes logo

Stock News

TCRT Stock’s Rollercoaster: What’s Next?

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
TCRT Stock’s Rollercoaster: What’s Next? Thumbnail

Alaunos Therapeutics Inc. stocks have been trading up by 18.11% as investor optimism surges on promising developments.

Candlestick Chart

Live Update At 09:18:31 EST: On Thursday, October 09, 2025 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 18.11%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Earnings Report and Financial Metrics

In the world of trading, understanding risk management is absolutely critical. Many traders find themselves chasing losses, resulting in financial strain and significant stress. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.” This emphasizes the importance of preserving your capital by knowing when to cut losses and avoid further financial setbacks. Rather than risking everything and ending up in debt, traders should focus on maintaining a balance and strategically managing their trades. The ability to walk away without losses is often more valuable than any potential quick gain that may lead to more serious issues down the line.

Alaunos Therapeutics Inc., commonly recognized by its ticker TCRT, showcases a financial snapshot that paints a picture of fluctuating fortunes. They report a daunting net loss of around $1M for their most recent quarter with revenues scraping at $10,000. Despite these lean numbers, the company exhibits a strong financial backbone with zero long-term debt and a current ratio of 3.5—indicative of sufficient cover for short-term obligations.

In terms of valuation, the company steers a delicate balance, influenced by its price-to-book ratio at 1.8 and enterprise valuation around $5.2M. Operational woes are evident with a negative profit margin at a staggering -570%. This gloom, however, contrasts with the optimism engendered by potential strategic initiatives outlined in tentative future-directed public communications.

Market Reactions to Earnings

The financial report has generated mixed sentiments in the market. On one hand, the formidable negative income and razor-thin revenue margins give pause to investors, evoking skepticism about growth prospects. On the other, optimism flickers among believers in Alaunos’ R&D capabilities and their potential to leverage strategic partnerships in the realm of cancer therapy innovations.

More Breaking News

Past trading data reveals intraday price zeniths and nadirs, reflective of both speculation and caution. This rollercoaster pattern serves as a mirror to investor sentiment, a sentiment in flux, constantly pivoting on news whispers and pending disclosures from the therapeutic innovator.

Implications of Strategic Partnerships

News circulates about appealing alliances in the healthcare sector for TCRT, stirring intrigue among market watchers. Proposals for partnerships aiming to revolutionize T-cell therapy could significantly bolster Alaunos’ market positioning. With increasing awareness and market interest in biotechnological breakthroughs, TCRT’s valuation can potentially swell if partnerships bear fruitful results.

Though financial performance poses concerns, it’s the whisperings of breakthroughs in the lab that are garnering anticipative nods. Such external collaborations, if secured, could drive unprecedented financial boons—revolutionizing market reception and potentially swinging valuation upwards.

Closing Conclusions

For TCRT, the current trading dance is a tango between risk and potential reward. Traders and analysts find themselves at a crossroads—tethered to ground realities of financial setbacks, yet tantalized by future therapies’ potential metamorphosis. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”

Volatility will likely continue to characterize TCRT’s ride in the financial markets, with near-term movements hinging on news developments and strategic maneuvers in their R&D labs. Both experienced and new traders are heeding the pulses of market data and the whispers of partnerships, holding collective breaths for a breakout that promises innovation and growth.

Stepping into TCRT’s narrative today presents a leap into uncertainty laced with promise—a dance on the edge, performed amidst swirling hypotheses, medical breakthroughs, and market aspirations.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”